Caprice Resources Ltd
- Country
- Ownership
- -
- Employees
- -
- Market Cap
- -
- Introduction
Crestview Exploration Inc is a technology-driven, well-funded, and experienced exploration company focused on finding gold and silver deposits in mining-friendly jurisdictions. The Rock Creek, Divide, and Castile Mountain properties are situated in the Tuscarora Mountains of northern Elko County, Nevada. It has one operating segment, the sector of exploration and evaluation of mineral resources. The company's Tuscarora properties combined comprise a total of 101 unpatented lode mining claims, with 74 claims at Rock Creek, 19 claims at Divide, and 8 claims at Castile Mountain.
Poolbeg Pharma Secures £4.1 Million Fundraising to Advance Clinical Programs in Oncology and Obesity
Poolbeg Pharma has announced a £4.1 million conditional fundraising to advance its POLB 001 Phase 2a trial for cancer immunotherapy-induced Cytokine Release Syndrome and oral GLP-1 proof of concept trial for obesity.
FDA Grants Orphan Drug Designation to Poolbeg Pharma's POLB 001 for Cancer Immunotherapy-Induced Cytokine Release Syndrome
The FDA has granted Orphan Drug Designation to POLB 001, an oral p38 MAP kinase inhibitor designed to prevent or treat cytokine release syndrome (CRS) induced by T-cell engager bispecific antibodies.
Tarlatamab for SCLC: Comprehensive Administration Protocol and Patient Selection Guidelines
Tarlatamab, a novel bispecific antibody therapy for relapsed/refractory small cell lung cancer, is administered via intravenous infusion every three weeks with a step-up dosing approach to minimize adverse reactions.
Autolus Reports Promising Long-Term Data for Obe-cel in Relapsed/Refractory B-ALL at EHA Congress
Autolus Therapeutics presented updated clinical data showing 40% of responders to obecabtagene autoleucel (obe-cel) maintained remission for ≥3 years without subsequent stem cell therapy, suggesting potential as a definitive treatment for r/r B-ALL.
CytoAgents Advances Phase 1b/2a Trial of CTO1681 for Cytokine Release Syndrome in CAR T-Cell Therapy Patients
CytoAgents has successfully completed the first dose cohort of its Phase 1b/2a trial for CTO1681, showing a favorable safety profile with no dose-limiting toxicities in DLBCL patients receiving CAR T-Cell therapy.
Cardiovascular Risks of Tisagenlecleucel in Pediatric Patients: New FAERS Analysis Reveals Critical Safety Signals
Analysis of FDA Adverse Event Reporting System reveals that nearly one-third (32.92%) of pediatric patients receiving tisagenlecleucel CAR T-cell therapy experienced cardiovascular adverse events, with hypotension being the most common complication.
Axi-Cel Therapy Shows Reduced Toxicities in Large B-Cell Lymphoma Treatment
Axicabtagene ciloleucel (axi-cel) therapy demonstrates a significant decrease in the severity and duration of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).
Rapcabtagene Autoleucel Shows High Remission Rates in Relapsed/Refractory DLBCL
Rapcabtagene autoleucel, a CD19-directed CAR T-cell therapy, demonstrated an 88.3% overall response rate in patients with relapsed/refractory DLBCL.
Obe-cel CAR T-cell Therapy Shows High Response Rates in Relapsed B-cell ALL
Obecabtagene autoleucel (obe-cel) demonstrates a 76.6% overall response rate and a 55.3% complete remission rate in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL).
FDA Approves Obecabtagene Autoleucel (Obe-cel) for Relapsed/Refractory B-Cell ALL
The FDA has approved obecabtagene autoleucel (obe-cel; Aucatzyl) for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).